Meet the company making masks for immunotherapies

Immuno-oncology therapies like the melanoma-treating Yervoy can lead to complete remissions, but for some patients, the benefits come with troublesome toxicities.

With that in mind, the startup Akrevia Therapeutics is at work on what it calls a masking technique. As STAT’s Kate Sheridan reports, the idea is to craft proteins that could be affixed to antibody therapies and prevent them from attacking anything other than their target tumors.

The company, still in the preclinical stages of development, is working off a $30 million series A round closed in 2018.

Read more.